Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances
Apricus Biosciences (Nasdaq: APRI) (http://www.apricusbio.com) announced today that the Canadian Intellectual Property Office issued a Notice of Allowance for a Canadian patent on certain methods of manufacture for the Company's platform NexACT® drug delivery technology.
Specifically, the patent covers the synthesis of Dodecyl 2-(N, N-Dimethylamino)-Propionate (DDAIP) by a transesterification chemical process. DDAIP opens up the tight junctions between cells, allowing drugs to be delivered to the bloodstream.
The patent application (No. 2,706,680), entitled "Crystalline Salts of Dodecyl 2-(N, N-Dimethylamino)-Propionate, is a divisional application of the already issued Canadian Patent No. 2,338,139 bearing the same title and covering crystal salts of DDAIP. When issued, this patent will protect this method of manufacture of DDAIP in Canada, and provides patent exclusivity to May 2020.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.